# RASolute 304 (NCT07252232)

> Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07252232
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma (PDAC); Resected Pancreatic Adenocarcinoma
- Interventions: daraxonrasib
- Enrollment: 500
- Primary outcome: Disease-Free Survival (DFS) per Investigator

## Commentary we found

- YouTube: 4
- Podcasts: 3
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=rasolute-304-nct07252232

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07252232", "email": "<work email>"}; the inbox owner confirms by the emailed link.